Journals / Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi / 2021 / Cilt: 16 - Sayı: 1

The efficacy of fractional CO2 laser (FemiLift™) treatment in postmenopausal females with vulvovaginal atrophy: Preliminary results from a single center in Turkey

Postmenopozal Vulvovajinal Atrofi Saptanan Kadınlarda Fraksiyonel CO2 Lazer (Femilift™) Tedavisinin Etkinliği: Türkiye'den Tek Bir Merkezin Ön Sonuçları

Pages
96–100
Publication Date
2021-02-08
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, this treatment can be considered to a reliable alternative for patients who do not wish to use local estrogen creams long-term, those with a history of breast or gynecological cancer, and those with contra-indications for the use of local estrogen.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Symptoms, such as vaginal laxity, dryness, dyspareunia, itching, burning, and urine leakage, associated with vulvovaginal atrophy (VVA) with hypo-osteogenesis etiology, are frequently seen in postmenopausal females, and they diminish quality of life.
📊
Key Findings & Data:This study aimed to evaluate the efficacy of CO2 laser treatment in these cases and to evaluate the potential side-effects related to this type of treatment.
💡
Conclusion & Impact:Thus, this treatment can be considered to a reliable alternative for patients who do not wish to use local estrogen creams long-term, those with a history of breast or gynecological cancer, and those with contra-indications for the use of local estrogen.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Vulvovaginal atrofi · CO2 lazer tedavisi · Hipoöstrojenemi

Abstract

Objective: Symptoms, such as vaginal laxity, dryness, dyspareunia, itching, burning, and urine leakage, associated with vulvovaginal atrophy (VVA) with hypo-osteogenesis etiology, are frequently seen in postmenopausal females, and they diminish quality of life. This study aimed to evaluate the efficacy of CO2 laser treatment in these cases and to evaluate the potential side-effects related to this type of treatment. Materials and Methods: A retrospective examination was made of the clinical examination and treatment records of 30 patients, aged 48–72 years, who presented with VVA complaints and underwent CO2 laser treatment for a total of three sessions at intervals of 4–6 weeks. The VVA symptoms of all the patients were evaluated using a Visual Analog Scale (VAS) before the first laser session and 4 weeks after the final session. Results: The VVA symptoms of dryness, painful sexual relations, vaginal burning, itching, and vaginal introitus pain were evaluated with VAS scores; a statistically significant reduction was determined in all five symptoms after CO2 laser treatment. Conclusion: A significant reduction was obtained in the VVA complaints with no significant side-effects following the application of CO2 laser treatment for VVA cases in the postmenopausal females. Thus, this treatment can be considered to a reliable alternative for patients who do not wish to use local estrogen creams long-term, those with a history of breast or gynecological cancer, and those with contra-indications for the use of local estrogen.

Özet

Amaç: Etyolojisinde hipoöstrojenemi olan Vulvovajinal atrofiye (VVA) bağlı gelişen vajinal laksite, kuruluk, disparoni, kaşıntı, yanma, idrar kaçırma gibi semptomlar postmenopozal kadınlar arasında sık görülen ve yaşam kalitesini azaltan durumlardır. Bu çalışmamızda bu olgularda uyguladığımız CO2 lazer tedavisinin etkinliğini ve bu tür tedaviyle ilgili olası yan etkileri değerlendirmeyi amaçladık. Gereç ve Yöntemler: 48-72 yaş arasında VVA şikayetleri olan ve buna yönelik 4-6 hafta ara ile toplam 3 seans CO2 lazer tedavisi uyguladığımız 30 hastanın klinik muayene ve tedavi kayıtları retrospektif olarak incelenmiştir. Tüm hastaların ilk lazer seansından önce ve son seanstan 4 hafta sonra VVA semptomları görsel analog skala (VAS) kullanılarak değerlendirilmişti. Bulgular: Olguların VVA semptomları olarak kuruluk, ağrılı cinsel ilişki, vaginal yanma, kaşıntı ve vajinal introitus ağrısı açısından VAS skorları değerlendirildiğinde her 5 semptom için de tedavi sonrası skorlarda istatistiksel olarak anlamlı düzeyde düşüşler tespit edilmiştir. Sonuç: VVA şikayetleri olan ileri yaş olgulara yönelik yapılan CO2 lazer tedavisi şikayetlerde kayda değer oranda yan etki görülmeden anlamlı düzeyde azalma sağlar. Böylece uzun süreli lokal östrojen kremleri kullanmak istemeyen ve meme ve genital jinekolojik kanser geçmişi olup lokal östrojen kullanması kontrendike olan hastalarda güvenilir bir alternatif olabilir.

🔖

Cite This Article

BAKACAK, Z. (2021). The efficacy of fractional CO2 laser (FemiLift™) treatment in postmenopausal females with vulvovaginal atrophy: Preliminary results from a single center in Turkey. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi, Cilt: 16 - Sayı: 1, 96–100. https://ajindex.com/articles/783260

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85(1):87-94
  2. Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA) results from an international survey. Climacteric 2012;15(1):36-44
  3. Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009;63(2):138-141
  4. Yoo C, Yun MR, Ahn J-H, Jung KH, Kim HJ, Kim JE, et al. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study. Cancer Chemother Pharmacol 2013;72(3):565–575
  5. Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 2015;18(2):121-134
  6. Kaufmann R, Hibst R. Pulsed Erbium:YAG laser ablation in cutaneous surgery. Lasers Surg Med. 1996;19(3):324-330
  7. Prignano F, Campolmi P, Bonan P, Ricceri, F, Cannarozzo G, Troiano M, et al. Fractional CO2 laser: a novel therapeutic device upon photobiomodulation of tissue remodeling and cytokine pathway of tissue repair. Dermatol Ther 2009;22 Suppl 1: S8-15
  8. Salvatore S, Leone Roberti Maggiore U, Origoni, M, Candiani M, Calligaro A, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause 2015;22(8):845-849
  9. Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference P. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Climacteric 2014;17(5):557–563
  10. Tadir Y, Gaspar A, Lev-Sagie A, Alexiades M, Alinsod R, BaderA, et al. Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med 2017;49(2):137–159
  11. Samuels JB, Garcia MA. Treatment to external labia and vaginal canal with CO2 laser for symptoms of vulvovaginal atrophy in postmenopausal women. Aesthet Surg J 2019;39(1):83–93
  12. Athanasiou S, Pitsouni E, Falagas ME, Salvatore S, Grigoriadis T. CO2 laser for the genitourinary syndrome of menopause. How many laser sessions? Maturitas 2017;104:24–28
  13. Sokol ER, Karram MM. An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause 2016;23(10):11